Patients with idiopathic normal pressure hydrocephalus (iNPH) who also carried Alzheimer's disease pathology before surgery showed no short-term difference in cognitive outcomes after cerebrospinal fluid shunting compared with those who did not, according to a systematic review and meta-analysis published online in Movement Disorders on 4 May 2026. Ameya Patwardhan, Mojtaba Sharafkhah, Michael Borrie and Jaspreet Bhangu, of Western University and St Joseph's Health Care in London, Ontario, searched PubMed, Embase, Scopus and Web of Science following PRISMA reporting standards, and identified 16 studies covering 1,825 patients, of which nine studies covering 428 patients could be pooled statistically. Prevalence of pre-shunt Alzheimer's co-pathology ranged from 23.9% to 67.6% across the included studies, and follow-up ran from 3 to 60 months.

Using random-effects models that pooled standardised mean differences, the authors split follow-up into short term (under 12 months) and long term (12 months or more). Cognitive outcomes showed no group difference in the short term but a significant long-term group effect, with poorer cognitive recovery in the group that had Alzheimer's co-pathology. Gait ran the other way: measures favoured the group without Alzheimer's pathology in the short term, with no group effect at long-term follow-up. Urinary outcomes showed no group difference at any follow-up point. The authors conclude that Alzheimer's pathology is not a contraindication to shunting, and that biomarker assessment belongs in the pre-shunt workup as a guide to what to expect rather than as a gate.

The question matters because iNPH is one of the few causes of cognitive and gait decline in seniors that can be treated surgically, and because Alzheimer's changes are common in the same age group. A prospective population-based study in the Swedish county of Jamtland, published in PLOS One in 2019, put the prevalence of probable iNPH at 3.7% among residents aged 65 and over, rising to 8.9% in those aged 80 and above. Guidance from the Japanese Society of Normal Pressure Hydrocephalus, whose third-edition management guidelines appeared in Neurologia medico-chirurgica in January 2021, already set out an algorithm for diagnosis and shunt decision making, and clinics differ in how much weight they give to amyloid or tau findings from cortical biopsy taken at surgery or from cerebrospinal fluid testing.

The counterpoint sits inside the method. Every pooled study was observational, patients were not randomly assigned, and the definition of Alzheimer's co-pathology varied between cohorts, from biopsy histology to biomarker thresholds. Only 428 of the 1,825 reviewed patients contributed to the pooled estimates, follow-up windows differed widely, and gait, cognition and continence were each measured with different instruments across studies, which makes the domains hard to compare directly with one another.